Biosidus S.A.U.

Biosidus is engaged in the development, manufacturing and commercialization of high-quality recombinant proteins. Since the launch of Erythropoetin in 1990, Biosidus has successively marketed the following biosimilars: Interferon Alfa 2a, Interferon Alfa 2b, Filgrastim, Somatropin, Lenograstim, Azacitidine, Bortezomib, Interferon beta 1a (SC and IM) and Teriparatide. Today, these products are being commercialized in more than 50 markets.
With headquarters and manufacturing plants located in Buenos Aires, Argentina, we have developed regional hubs in order to intensify our pres...